RxDoctor Payments Data

Morgan Brown

Nurse Practitioner · Waukee, IANPI 1710419726

Payments from drug & device makers

$1,035in general payments, 2019–2025

Across 36 payments — averaging $28.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$277
  • Boston Scientific$114
  • Biotronik NRO, Inc.$82
  • Collegium Pharmaceutical, Inc.$76
  • Redhill Biopharma Inc.$71
  • Biohaven Pharmaceuticals, Inc.$66
  • plus $349 from 9 others

What the payments were for

  • Food & beverage$1,02199%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,035 in reported general payments places this provider in the 85th percentile of 1,346 nurse practitioner providers in Iowa.

See all nurse practitioner providers in Iowa

Medicare billing

Part B allowed, 2024
$13,274
Medicare patients
61
Services billed
172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl73$29,928
Fentanyl96$15,840
Oxymorphone Hcl ErOxymorphone Hcl24$14,785
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen439$13,997
Xtampza ErOxycodone Myristate27$13,171
Oxycodone Hcl664$13,163
LinzessLinaclotide15$9,065
Morphine Sulfate ErMorphine Sulfate312$7,287
ButransBuprenorphine12$6,160
Pregabalin268$5,665
SymproicNaldemedine Tosylate13$5,653
Buprenorphine25$5,299
Hydromorphone Hcl159$4,769
MovantikNaloxegol Oxalate11$4,515
Gabapentin160$2,960

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$76$13,17127 claims
AbbVieLinzess$277$9,06515 claims
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate$14$6,97667 claims
Redhill Biopharma Inc.Movantik$71$4,51511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,346 nurse practitioner providers in Iowa.

Other nurse practitioner in Waukee

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →